版本:
中国

BRIEF-Aimmune Therapeutics expects artemis to enroll 120-160 patients in Europe

Nov 28 Aimmune Therapeutics Inc:

* Aimmune Therapeutics completes global enrollment of phase 3 palisade trial of ar101 for the treatment of peanut allergy

* Says expects Artemis to enroll between 120 and 160 patients at multiple sites in Europe, beginning in mid-2017

* Aimmune - continues to expect topline data from palisade in q4 of 2017, followed by regulatory submissions for marketing approval of ar101 in 2018 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐